BridgeMD
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants with Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in combination with Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib
EU CTIS ID: 2024-515770-27-00
What this study is testing
- To characterize the safety, toxicity, and tolerability of etentamig monotherapy or in combination with other agents in participants with multiple myeloma (MM). - To determine the recommended doses of etentamig monotherapy or in combination with other agents in participants with MM.
- Phase I and Phase II (Integrated)- Other
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Eastern cooperative oncology group (ECOG) performance of <= 1.
- Confirmed diagnosis of multiple myeloma (MM) according to the International Myeloma Working Group (IMWG) diagnostic criteria with either newly diagnosed or relapsed or refractory (RR) MM, depending on the substudy.
- Laboratory values meeting the criteria outlined in the protocol for each substudy within the screening period prior to the first dose of study treatment.
You likely can't join if
- Participant who has known active central nervous system involvement of MM.
- Participant who has known active infection as outlined in the protocol.
- Participant who has known history or other active malignancies within the past 3 years with the exceptions listed in the protocol.
- Participant who has known history of clinically significant (per investigator's judgment) alcohol abuse within the last 6 months.
The study team makes the final eligibility decision.
Where it's taking place
- Australia
- Canada
- United Kingdom
- Israel
- Korea, Republic of
- Japan
- United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Australia; Canada; United Kingdom; Israel; Korea, Republic of; Japan and 1 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.